
Takeda has acquired PvP Biologics following the conclusion of a Phase 1 study of the investigational medicine TAK-062 for the …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

